Re: Farmas USA
ACAD
Buena subida en PM! Se ve que gustaron los resultados, y que al final el precio de Nuplazid será bastante mayor de lo que estimaban los analistas:
Acadia Pharmaceuticals Inc. priced its Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin) at $1,950 for a 30-day supply, which was significantly higher than Wall Street expected. With the US approval of Nuplazid in PDP in hand, the company is now focused on its development programs for the drug as a treatment for Alzheimer's disease psychosis and Alzheimer's agitation.